Q3 2022 Results
Company overview
Financial review
2022 priorities
Financial performance
Innovation: Pipeline overview
Cardiovascular
Immunology
Neuroscience
Ophthalmology
Global Health
CoartemⓇ PGH-1
NCT04300309 CALINA (CCOA566B2307)
Malaria, uncomplicated (<5kg patients)
Phase 3
Indication
Phase
Patients
44
Primary
Outcome
Measures
Artemether Cmax
Arms
Intervention
Target
Patients
Experimental: artemether lumefantrine (2.5 mg:30 mg)
artemether lumefantrine (2.5 mg:30 mg) bid over 3 days, from 1-4 tablets
per dose
Infants and Neonates <5 kg body weight with acute uncomplicated
plasmodium falciparum malaria
Primary outcome measure: 2023
Read-out
Milestone(s)
Publication
TBD
Appendix
Innovation: Clinical trials
References
Abbreviations
Oncology
Other
Biosimilars
90 Investor Relations | Q3 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation